Precision Biologics, Inc   Report issue

For profit Phase 1 Phase 2
Founded: Dallas TX United States (2012)
Status: Acquired by NantWorks (2015)

Organization Overview

First Clinical Trial
2012
NCT01040000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Precision Biologics, Inc

Active Ingredients

Drugs in Phase 2 Trials (3)

ensituximab (2 trials)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (1)

neo-201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adenocarcinoma, Mucinous (Phase 1)

Adenocarcinoma of Lung (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Signet Ring Cell (Phase 1)

Colorectal Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4